ity Review Status by U S FDA
Selected Abstract
Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA.
KENILWORTH, N.J., Jan. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the company's New Drug Application (NDA) for sugammadex. Sugammadex is specifically designed to reverse the effects ... January 2, 2008; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles No Results Found.
|
